source
- Iopofosine I-131 shows high response rates and durable disease control in Waldenstrom macroglobulinemia trialThe 12‑month follow‑up from the CLOVER‑WaM study reports that patients receiving Iopofosine I‑131 achieved strong clinical activity in Waldenstrom macroglobulinemia. In the per‑protocol group, the…
- Expert outlines how to manage common skin and GI side effects of daraxonrasib in pancreatic cancerDr Pant, MD, a professor at MD Anderson Cancer Center, discussed the safety profile of daraxonrasib, a RAS(ON) multi-selective inhibitor being studied in pancreatic ductal adenocarcinoma. The drug…